A Phase I Trial of BAY 43-9006 for Patients With Recurrent or Progressive Malignant Glioma.

Trial Profile

A Phase I Trial of BAY 43-9006 for Patients With Recurrent or Progressive Malignant Glioma.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2014

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 08 Apr 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 May 2012 Additional lead trial centre identified and actual patient number is 47 as reported by ClinicalTrials.gov.
    • 02 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top